Chat with us, powered by LiveChat


Gastroesophageal Reflux Disease Therapeutics Market Report


Gastroesophageal Reflux Disease Therapeutics Market by Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-kinetic Agents), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032


Pages: 310

Sep 2023

Gastroesophageal Reflux Disease Therapeutics Overview

Gastroesophageal Reflux Disease (GERD) therapeutics include a range of treatments to manage and alleviate the symptoms of this chronic digestive disorder. GERD happens when stomach acid frequently flows back into the throat, leading to disturbance and inflammation. The essential goals of GERD therapy are to decrease acid and reflux episodes, promote the healing of esophageal injuries, and progress the patient's overall quality of life. Medications can change depending on the severity of the infection and individual factors. Initially, lifestyle and dietary modifications are prescribed, such as avoiding trigger foods, eating smaller suppers, and not lying down after eating. Over-the-counter antacids, H2 blockers, and stronger proton pump inhibitors (PPIs) can diminish acid formation. Prokinetic agents may, in some cases, be prescribed to progress esophageal motility and gastric purging. Surgical options like fundoplication or minimally invasive endoscopic procedures may be considered for more severe or unresponsive cases. Close collaboration with healthcare providers is crucial to determine the most suitable therapeutic plan involving lifestyle changes, medications, and regular follow-ups for long-term management.

Global Gastroesophageal Reflux Disease Therapeutics Market Analysis

The global gastroesophageal reflux disease therapeutics market size was $5.19 billion in 2022 and is predicted to grow with a CAGR of 2.58%, by generating a revenue of $6.59 billion by 2032.

COVID-19 Impact on Global Gastroesophageal Reflux Disease Therapeutics Market

The COVID-19 pandemic significantly impacted the gastroesophageal reflux disease therapeutics market. During the height of the pandemic, delayed diagnosis and treatment were observed as many individuals avoided seeking medical attention for non-emergency conditions, including GERD. Healthcare priorities shifted to managing COVID-19 cases, leading to reduced focus and resources for GERD care. Supply chain disruptions impacted the availability of GERD medications, affecting patient access and potentially leading to price fluctuations. Ongoing clinical trials for new GERD therapies were also affected, with enrollment and data collection disrupted. Lifestyle changes induced by the pandemic's stressors could have contributed to GERD symptoms' prevalence and severity. Telemedicine and digital health solutions were adopted to minimize exposure risks, but in-person visits remained critical for severe cases. Furthermore, the pandemic may have led to increased usage of over-the-counter GERD medications as people tried to avoid medical facilities.

Increasing Prevalence of Gastroesophageal Reflux Disease to Drive the Market Growth

The Gastroesophageal Reflux Disease (GERD) therapeutics market is driven by various factors. Firstly, the expanding prevalence of GERD worldwide is a significant driver, with components like lifestyle changes, dietary habits, and obesity contributing to the rise in cases. The growing aging population, moreover, plays a major role as older people are more susceptible to GERD due to age-related changes in the esophagus. Modern lifestyles with irregular eating habits, high-stress levels, and consumption of spicy and fatty foods trigger GERD symptoms, boosting the demand for therapeutics. Moreover, heightened awareness and improved diagnoses of GERD among patients and healthcare providers have led to a greater need for effective treatments. Advancements in treatment options, increased healthcare expenditure, and technological medical diagnosis and monitoring innovations also contribute to market growth. Government initiatives and awareness campaigns further promote the market. At the same time, comorbidities and lifestyle disorders drive the need for managing GERD through therapeutics, as it often coexists with other health conditions.

Patent Expirations to Restrain the Market Growth  

Several factors can restrain the gastroesophageal reflux disease therapeutics market. Patent expiry of existing GERD drugs can lead to the entry of generic versions, increasing competition, and lowering prices. Safety concerns and side effects associated with some medications may limit their adoption and use, reducing market demand. Non-pharmacological alternatives like lifestyle changes and dietary modifications can effectively manage GERD symptoms, leading to a preference for these options over pharmacological therapies. The lack of novel and more effective treatment options in the pipeline can also hinder market growth. Surgical interventions may be preferred when medications fail, impacting the demand for pharmaceutical treatments. Economic downturns and instability can affect healthcare spending and patient access to GERD therapeutics. Regulatory issues and delays in drug approvals can also impact the timely availability of new medications. Competition from over-the-counter medications, comorbidities, polypharmacy, lack of awareness, and underdiagnosis are additional factors that can restrain the GERD therapeutics market.

Increasing Awareness and Diagnosis to Drive Excellent Opportunities

The gastroesophageal reflux disease therapeutics market presents numerous opportunities for growth and development. One significant opportunity arises from the increasing awareness and diagnosis. Increased awareness and diagnosis of the condition also contribute to a growing patient population, leading to higher demand for GERD therapeutics. Moreover, ongoing advancements in treatment options, including research and development efforts in the pharmaceutical industry, are likely to introduce innovative and more effective drugs, improving patient outcomes. The aging population further adds to the potential market growth, as older people are more susceptible to GERD. Technological innovations in drug delivery and medical devices also promise to enhance treatment effectiveness and patient compliance. Additionally, the expansion of healthcare infrastructure, particularly in emerging economies, and the availability of over the counter (OTC) medications for GERD create new market prospects. The concept of personalized medicine and the exploration of combination therapies for treating GERD also open avenues for growth.

Global Gastroesophageal Reflux Disease Therapeutics Market Share, by Drug Type, 2022

The antacids sub-segment accounted for the highest market share in 2022. Antacids have dominated the gastroesophageal reflux disease therapeutics market for several reasons. First and foremost, they provide rapid relief from heartburn and acid reflux symptoms, a crucial factor for patients seeking immediate comfort. Additionally, their over-the-counter availability without needing a prescription makes them easily accessible for those experiencing mild or occasional symptoms. Furthermore, their affordability compared to prescription medications and minimal side effects contribute to their popularity among patients and healthcare providers. The brand recognition of well-established antacid products also plays a role in their continued dominance. However, it's important to note that the GERD therapeutics landscape may have evolved beyond antacids, with newer and more effective treatments such as proton pump inhibitors, H2 blockers, and prokinetics gaining prominence.

Global Gastroesophageal Reflux Disease Therapeutics Market Share, by Region, 2022

The North America gastroesophageal reflux disease therapeutics market generated the highest revenue in 2022. North America has dominated the gastroesophageal reflux disease therapeutics market due to various factors.  The region's advanced technological skills and extensive healthcare infrastructure have permitted the development and deployment of cutting-edge GERD treatments, including as proton pump inhibitors and H2 blockers, which have now become conventional alternatives. Additionally, North America's relatively high prevalence of GERD, driven by dietary habits, lifestyle choices, and obesity rates, has increased demand for therapeutics. Major pharmaceutical companies headquartered in the region have played a pivotal role in researching, producing, and marketing GERD medications, ensuring broad availability to patients. Moreover, North American countries' healthcare policies and awareness campaigns have promoted early diagnosis and treatment, improved patient management and increasing demand for GERD therapeutics. A favorable regulatory environment and market competitiveness have further fueled advancements in this sector.

Competitive Scenario in the Global Gastroesophageal Reflux Disease Therapeutics Market

Investment and agreement are common strategies followed by major market players. One of the leading market players in the industry is Adcock Ingram. For instance, in July 2022, Adcock Ingram launched dexlansoprazole, a PPI-modified release medication for the treatment of GERD. Some of the leading gastroesophageal reflux disease therapeutics market players are AstraZeneca, Eisai Co., Ltd., GSK plc., Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Adcock Ingram, SFJ Pharmaceuticals, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc.



Historical Market Estimations


Base Year for Market Estimation


Forecast Timeline for Market Projection


Geographical Scope

North America, Europe, Asia-Pacific, and LAMEA

Segmentation by Drug Type

  • Antacids
  • H2 Receptor Blockers
  • Proton Pump Inhibitors (PPIs)
  • Pro-kinetic agents

Key Companies Profiled

  • AstraZeneca
  • Eisai Co., Ltd.
  • GSK plc.
  • Takeda Pharmaceutical Company Limited.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • SFJ Pharmaceuticals
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • Camber Pharmaceuticals, Inc.

Frequently Asked Questions

A. The size of the global gastroesophageal reflux disease therapeutics market was over $1.60 billion in 2022 and is projected to reach $6.31 billion by 2032.

A. Phathom Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc. are some of the key players in the global gastroesophageal reflux disease therapeutics market.

A. The North America region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Agreement and investment are the two key strategies opted by the operating companies in this market.

A. Takeda Pharmaceutical Company Limited., Ironwood Pharmaceuticals, Inc., and Johnson & Johnson Services, Inc., are the companies investing more on R&D activities for developing new products and technologies.

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed